Document:

Filed by Bowne Pure Compliance

Exhibit 10.12

Option Agreement

This Option Agreement (the “AGREEMENT”) is made between the BOARD OF REGENTS (“BOARD”), of the
UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West
7th Street, Austin, Texas 78701, and ChromaDex (“OPTIONEE”), a corporation, with its principal
place of business at 2952 Daimler St., Santa Ana, CA 92705.

RECITALS

A. BOARD owns certain PATENT RIGHTS and TECHNOLOGY RIGHTS which were developed at the University of
Texas at El Paso (“UNIVERSITY”), a component institution of SYSTEM.

B. BOARD desires to have PATENT RIGHTS and TECHNOLOGY RIGHTS developed and used for the benefit of
OPTIONEE, the BOARD, INVENTOR, and the public as outlined in BOARD’S Intellectual Property Policy.

C. OPTIONEE wishes to obtain an option to negotiate and acquire a license from BOARD to practice
PATENT RIGHTS and TECHNOLOGY RIGHTS and sell and distribute products derived therefrom.

NOW THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties
agree as follows:

1. EFFECTIVE DATE AND OPTION PERIOD

This AGREEMENT is effective as of July 25, 2005 (“EFFECTIVE DATE”) for a period of 12 months (the
“OPTION PERIOD”),

2. DEFINITIONS

2.1 PATENT RIGHTS mean BOARD’S rights in improvements to information or discoveries covered by U.S.
Patent # 6,017,722 entitled, “Luminous Bacteria
and Methods for the Isolation, Identification and
Quantification of Toxicants,” U.S. Patent # 6,340,572, entitled, “Kit for the Isolation,
Identification and Quantification of Toxicants,” and U.S. Patent #6,673,563 entitled “Luminous
Bacteria and Methods for the Isolation, Identification and Quantification of Toxicants”, all
corresponding foreign patent applications; and all re-examinations or extensions thereof.

2.2 TECHNOLOGY RIGHTS mean BOARD’S rights in any technical information, know-how, process,
procedure, composition, method, formula, protocol, technique or data
developed by Dr. James Becvar,
Laura Becvar, and Olga Valerio (“INVENTORS”) at UNIVERSITY
prior to the EFFECTIVE DATE relating to
Lumibiotic Assay (UTEP No. 05-001), LumiGel Overlay (UTEP No. 05-002), and Multiplex Lumitection
Analysis (UTEP No. 05-003) which are not covered by PATENT RIGHTS.

 

 

 

2.3 LICENSED PRODUCT means any product which cannot be developed, manufactured, used or sold
without utilizing PATENT RIGHTS or TECHNOLOGY RIGHTS.

3. WARRANTIES

3.1 Except for the rights, if any of the Government of the United States, as set forth below, BOARD
hereby represents that it has the full right and power to enter into this AGREEMENT and to grant
the exclusive option set forth in this AGREEMENT. BOARD makes no other warranties concerning its
rights covered by this AGREEMENT. BOARD makes no expressed or implied warranty of merchantability
or fitness for a particular purpose as to any LICENSED PRODUCT. BOARD makes no warranty or
representation as to the validity or scope of the PATENT RIGHTS or that any LICENSED PRODUCT will
be free from an infringement of patents of third parties, or that no third parties are in any way
infringing PATENT RIGHTS.

3.2 OPTIONEE understands that the PATENT RIGHTS and TECHNOLOGY RIGHTS may have been developed under
a funding agreement with the Government of the United States of America and, if so, that the
Government may have certain rights relative thereto. This AGREEMENT is explicitly made subject to
the Government’s rights under any such agreement and any applicable law or regulation. To the
extent that there is a conflict between any such agreement, applicable law or regulation and this
AGREEMENT, the terms of such Government agreement, applicable law or
regulation will prevail.

4. OPTION FOR EXCLUSIVE LICENSE

4.1 BOARD hereby grants OPTIONEE an exclusive option to acquire an exclusive, worldwide license to
practice PATENT RIGHTS and TECHNOLOGY RIGHTS under terms set forth in the License Agreement
attached as Attachment A.

5. TERMINATION

5.1 OPTIONEE may terminate this AGREEMENT by giving 30 days written notice to UNIVERSITY.

5.2 UNIVERSITY may terminate this AGREEMENT upon 30 days written notice to OPTIONEE if OPTIONEE
breaches or defaults on its payments under Article 6 or its payments and obligations (including,
but not limited to, payment of patent expenses) as set forth in any related agreement between
OPTIONEE and
UNIVERSITY covering PATENT RIGHTS and/or TECHNOLOGY RIGHTS, unless, before the end of the 30 day
period, OPTIONEE has cured the breach or default to the satisfaction of UNIVERSITY and so notifies
UNIVERSITY in writing, stating the manner of the cure.

 

 

 

6. PAYMENT

6.1 In consideration for the option granted herein, OPTIONEE agrees to pay BOARD an option fee
equal to any out-of-pocket patent and licensing expenses, credible toward a license fee upon
election of the option to license, to be payable in four equal payments the first due upon
execution of this Agreement by Licensee and the other three payments due every calendar quarter;

6.2 All payments under this AGREEMENT are to be paid in U.S. dollars, checks payable to the order
of UNIVERSITY and mailed to the address in Section 8.6.

7. CONFIDENTIAL INFORMATION

7.1 As soon as possible following the execution of this AGREEMENT, UNIVERSITY, through INVENTOR,
will disclose all relevant Confidential Information as defined in Section 7.2 below, other
information, and data relating to PATENT RIGHTS and TECHNOLOGY RIGHTS, to enable OPTIONEE to
evaluate the potential commercial significance of the PATENT RIGHTS and TECHNOLOGY RIGHTS.

7.2 In
addition to the initial disclosure described in Section 7.1, the parties may disclose other
Confidential Information to each other, from time to time, in connection with work contemplated
under this AGREEMENT. All such information whether disclosed Initially or during the OPTION PERIOD
will be referred to as “Confidential Information.” Each party will use reasonable efforts to
prevent the disclosure of any of the other party’s Confidential Information to third parties for a
period of three (3) years after the termination of this AGREEMENT, provided that the recipient
party’s obligation will not apply to information that:

a. is not disclosed in writing or reduced to writing and so marked with an appropriate
confidentiality legend within thirty (30) days of disclosure;

b. is already in the recipient party’s possession at the time of disclosure thereof and not
obtained directly or indirectly from the other, as proven by the receiving party’s written records;

c. is or later becomes published through no fault of the recipient party;

d. is lawfully acquired from a third party having no obligations of confidentiality to the
disclosing party;

e. is independently developed by the recipient party; or

f. is required by law or regulation to be disclosed.

 

 

 

7.3 In the event that information is required to be disclosed under Section 7.2(f) above, the party
required to make disclosure will notify the other to allow that party to assert whatever exclusions
or exemptions may be available to it under such law or regulation.

8. GENERAL PROVISIONS

8.1 This AGREEMENT may not be assigned by OPTIONEE without the prior written consent of BOARD,
which consent may not unreasonably be withheld. However, OPTIONEE may assign any and all of the
rights granted to it pursuant to this AGREEMENT to a successor of all or substantially all of its
business to which this AGREEMENT relates without the approval from or prior notice to BOARD.

8.2 This AGREEMENT constitutes the entire and only agreement between the parties relating to an
option to acquire a license, and all prior negotiations, representations, agreements and
understandings are superseded hereby. No agreements altering or supplementing the terms hereof may
be made except by written mutual agreement by the parties.

8.3 The relationship between UNIVERSITY and OPTIONEE is that of independent contractors. UNIVERSITY
and OPTIONEE are not joint ventures, partners, principal and agent, master and servant, employer or
employee, and have no other relationship other than independent contracting parties. UNIVERSITY
will have no power to bind or obligate OPTIONEE in any manner, other than as is expressly set forth
in this AGREEMENT. Likewise OPTIONEE will have no power to bind or obligate UNIVERSITY in any
manner, other than as is expressly set forth in this AGREEMENT.

8.4 If any provision of this AGREEMENT is ultimately held to be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remaining provisions will not in any way be
affected or impaired thereby.

8.5 Any delay in enforcing a party’s right under this AGREEMENT or any waiver as to a particular
default or other matter will not constitute a waiver of such party’s rights to the future
enforcement of its rights under this AGREEMENT, except only as to an express written and signed
waiver to a specific matter for a specific period of time.

 

 

 

8.6 Any notice required by this AGREEMENT will be given by personal delivery (including delivery by
reputable messenger services such as Federal Express) or by prepaid, first class, certified mail,
return receipt requested, addressed to:

The University of Texas at El Paso

Technology Transfer Office

Burges Hall, Room 404

500 W. University

El Paso, Texas 79968

Attn: Technology Transfer Manager

Ph: 915/747-7901

Fax: 915/747-5931

or in the
case of OPTIONEE to:

ChromaDex

2952 Daimler St.

Santa Ana, California 92705

Attn: Frank Jaksch

Fax: 949/419-0894

Phone: 949/419-0288

or at
such other addresses as may be given from time to time in accordance with the terms of this
notice provision.

8.7 This AGREEMENT will be governed by, construed, and enforced in accordance with the internal
laws of the State of Texas.

IN WITNESS WHEREOF, the parties have caused this AGREEMENT to be executed by their duly authorized
representatives.

	 	 	 	 	 	 	 	 	 	 	 
	BOARD OF REGENTS OF THE

UNIVERSITY OF TEXAS SYSTEM	 	 	 	CHROMADEX	 	 
	 

	 	 	 	 
	 	 	 	 	 	 
	By

	 	 	 	 	 	By
	 	/s/ Frank Jaksch	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Diana S. Natalicio, President
	 	 	 	 	 	Frank Jaksch, President	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	 	 	 	 	Date:
	 	August 19, 2005	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Approved as to Content:	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	Paul C. Maxwell, Vice President	 	 	 	 	 	 	 	 
	 

	 	For Research & Sponsored Projects	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 

 

 

 

ATTACHMENT A

 

 

 

PATENT LICENSE AGREEMENT

THIS Agreement is between the Board of Regents (“Board”) of The University of Texas System
(“System”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas
78701, and ChromaDex, a corporation having a principal place of business located at 2952 Daimler
St., Santa Ana, CA 92705 (“Licensee”).

TABLE OF CONTENTS

	 	 	 	 	 
	RECITALS
	 	 	2	 
	 
	 	 	 	 
	1. EFFECTIVE DATE
	 	 	2	 
	 
	 	 	 	 
	2. DEFINITIONS
	 	 	2	 
	 
	 	 	 	 
	3. WARRANTY, SUPERIOR RIGHTS AND REPRESENTATIONS
	 	 	4	 
	 
	 	 	 	 
	4. LICENSE
	 	 	5	 
	 
	 	 	 	 
	5. PAYMENTS AND REPORTS
	 	 	5	 
	 
	 	 	 	 
	6. TERM AND TERMINATION
	 	 	8	 
	 
	 	 	 	 
	7. INFRINGEMENT BY THIRD PARTIES
	 	 	10	 
	 
	 	 	 	 
	8. ASSIGNMENT
	 	 	10	 
	 
	 	 	 	 
	9. PATENT MARKING
	 	 	10	 
	 
	 	 	 	 
	10. INDEMNIFICATION AND INSURANCE
	 	 	10	 
	 
	 	 	 	 
	11. USE OF BOARD AND COMPONENT’S NAME
	 	 	11	 
	 
	 	 	 	 
	12. CONFIDENTIAL INFORMATION AND PUBLICATION
	 	 	11	 
	 
	 	 	 	 
	13. PATENTS AND INVENTIONS
	 	 	12	 
	 
	 	 	 	 
	14. ALTERNATE DISPUTE RESOLUTION
	 	 	13	 
	 
	 	 	 	 
	15. GENERAL
	 	 	13	 
	 
	 	 	 	 
	SIGNATURES
	 	 	14	 

 

 

 

RECITALS

A. Board owns certain Patent Rights and Technology Rights related to Licensed Subject Matter, which
was developed at The University of Texas El Paso (“University”), a component institution of System.

B. Board desires to have the Licensed Subject Matter developed and used for the benefit of
Licensee, Inventor, Board, and the public as outlined in Board’s Intellectual Property Policy.

C. Licensee wishes to obtain a license from Board to practice Licensed Subject Matter.

NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties
agree as follows:

1. EFFECTIVE DATE

This Agreement is effective August 19, 2005 (“Effective Date”).

2. DEFINITIONS

As used
in this Agreement, the following terms have the meanings indicated:

2.1 “Affiliate” shall mean any individual or entity directly or indirectly controlling, controlled
by or under common control with, a party to this Agreement. For purposes of this Agreement, the
direct or indirect ownership of over fifty percent (50%) of the outstanding voting securities of an
entity, or the right to receive over fifty percent (50%) of the profits or earnings of an entity
shall be deemed to constitute control. Such other relationship as in fact gives such Individual or
entity the power or ability to control the management, business and affairs of an entity shall also
be deemed to constitute control.

2.2
“Licensed Field” means all fields.

2.3 “Licensed Product” means any product, composition, method or process which, in the course of
manufacture, use, practice, sale or Import is:

(a) within the scope of one or more claims of the Patent Rights; or

(b) a product containing any one or more of the following or similar elements and which is intended
to be used as part of any product, composition, method or process which is within the scope of one
or more claims of the Patent Rights:

(i) Analytical chemistry media (i.e. TLC plates);

 

2

 

(ii) luminescent bacteria for detection (stabilized);

(iii) chemicals and reagents for performing steps covered under the Patent Rights;

(iv) detection devices or media; and/or

(v) instruction manual describing or inducing one to perform the steps covered under
the Patent Rights.

2.4 “Licensed Subject Matter” means Inventions and discoveries covered by Patent Rights
or Technology Rights within Licensed Field.

2.5 “Licensed Territory” means the worldwide.

2.6 “Net Sales” means the gross revenues received by Licensee, affiliates, or sublicensees
from the Sale of Licensed Products less sales and/or use taxes actually paid, import and/or export
duties actually paid, outbound transportation prepaid or allowed, and amounts allowed or credited
due to returns (not to exceed the original billing or invoice amount). Transfer of a licensed
product within licensee or between licensee and an affiliate for sale by the transferee shall not
be considered a Net Sale for purposes of ascertaining royalty charges. In such circumstances, the
gross sales price and resulting net sales price shall be based upon
the sale of the licensed
product by the transferee.

2.7 “Patent Rights” means Board’s rights in improvements to information or discoveries covered
by U.S. Patent # 6,017,722 entitled, “Luminous Bacteria and Methods for the Isolation,
Identification and Quantification of Toxicants,” U.S. Patent # 6,340,572, entitled, “Kit for
the Isolation, Identification and Quantification of
Toxicants,“and U.S. Patent #6,673,563
entitled “Luminous Bacteria and Methods for the Isolation, Identification and Quantification
of Toxicants”, all corresponding foreign patent applications; and all re-examinations or
extensions thereof.

2.8 “Sale, Sell or Sold” means the transfer or disposition of a Licensed Product for value to a
party other than Licensee.

2.9 “Technology Rights” means Board’s rights in any technical information, know-how, process,
procedure, composition, method, formula, protocol, technique or data developed by Dr. James
Becvar, Laura Becvar, and Olga Valerio and other employees (“INVENTORS”) at UNIVERSITY prior
to or subsequent to the EFFECTIVE DATE relating to Lumibiotic Assay (UTEP No. 05-001), LumiGel
Overlay (UTEP No. 05-002), and Multiplex Lumitection Analysis (UTEP No. 05-003) which are not
covered by PATENT RIGHTS.

 

3

 

2.10 “Improvements” means Board’s rights in any technical information, know-how, process,
procedure, composition, method, formula, protocol, technique or data developed by University
which are not covered by Patent Rights but which would require the use of Patent Rights to
execute.

2.11 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months
ending on: March 31, June 30, September 30 and December 31.

3. WARRANTY: SUPERIOR-RIGHTS

3.1 Except for the rights, if any, of the Government of the United States, as set forth
below, Board represents and warrants its belief that (i) it is the owner of the entire right,
title, and interest in and to Licensed Subject Matter, (ii) it has the sole right to grant
licenses thereunder, and (iii) it has not knowingly granted licenses thereunder to any other
entity that would restrict rights granted to Licensee except as stated herein.

3.2 Licensee understands that the Licensed Subject Matter may have been developed under a
funding agreement with the Government of the United States of America and, if so, that the
Government may have certain rights relative thereto. This Agreement is explicitly made subject to
the Government’s rights under any agreement and any applicable law or regulation. If there is a
conflict between an agreement, applicable law or regulation and this Agreement, the terms of the
Government agreement, applicable law or regulation shall prevail.

3.3 Licensee understands and acknowledges that Board, by this Agreement, makes no representation as
to the operability or fitness for any use, safety, efficacy, ability to obtain regulatory approval,
patentability, and/or breadth of the Licensed Subject Matter. Board, by this Agreement, also makes
no representation as to whether there are any patents now held, or which will be held, by others or
by Board in the Licensed Field, nor does Board make any representation that the inventions
contained in Patent Rights do not infringe any other patents now held or that will be held by
others or by Board.

3.4 Licensee, by execution hereof, acknowledges, covenants and agrees that it has not been
induced in any way by Board, System, University or its employees to enter into this Agreement,
and further warrants and represents that (i) it has conducted sufficient due diligence with
respect to all items and issues pertaining to this Article 3 and all other matters pertaining
to this Agreement; and (ii) Licensee has adequate knowledge and expertise, or has utilized
knowledgeable and expert consultants, to adequately conduct the due diligence, and agrees to
accept ail risks inherent herein.

 

4

 

4. LICENSE

4.1 Board hereby grants to Licensee a royalty-bearing, exclusive license under Licensed Subject
Matter including all improvements from the effective date going forward without any increase in
Royalty rate percentage, to manufacture, have manufactured, to sell or have sold, to use and have
used, to practice and have practiced any Licensed Products within the Licensed Territory for use
within Licensed Field. This grant is subject to the payment by Licensee to Board of all
consideration as provided herein, and is further subject to rights retained by Board to:

	 	a.	 	Publish the general scientific findings from research related to Licensed Subject Matter
subject to the terms of Section 12, Confidential Information; and
	 
	 	b.	 	Use Licensed Subject Matter for research, teaching and other educationally-related purposes,
subject to the terms of Section 12.

4.2 Licensee may extend the license granted herein to any Affiliate if the Affiliate consents to
be bound by this Agreement to the same extent as Licensee.

4.3 Licensee may grant sublicenses consistent with this Agreement if Licensee is responsible for
the operations of its sublicensees relevant to this Agreement as if the operations were carried
out by Licensee, including the payment of royalties whether or not paid to Licensee by a
sublicensee. Licensee must deliver to Board a true and correct copy of each sublicense subject to
confidentiality granted by Licensee, and any modification or termination thereof, within 30 days
after execution, modification, or termination. When this Agreement is terminated, all existing
sublicenses granted by Licensee must be assigned to Board and Board agrees to accept and honor
such sublicenses.

5. PAYMENTS AND REPORTS

5.1 In consideration of rights granted by Board to Licensee under this Agreement, Licensee will
pay Board the following:

	 	a.	 	A nonrefundable license documentation in the amount of
______, to be payable in four equal payments
the first due upon execution of this Agreement by Licensee and the other three payments due the
end of the first month of each Calendar Quarter, every successive Calendar Quarter until paid in
full;

 

5

 

	 	b.	 	A running royalty equal to one and three quarters percent (1.75%) of world wide Net Sales of
Licensed Products by Licensee, its Affiliates and Sublicensees, to be decreased by twenty-five
percent (25%) of the percentage of any additional licenses from third parties reasonably
required
to commercialize any given Licensed Product, but only as to such Licensed Product, and in no event
to be reduced to less than one and one half percent (1.50%) of Net Sales. Royalties will be paid on
all products world wide, without regard to whether there are Patent Rights in any country other
than the United States. The Antistacking provision would not apply to license agreements cross
referenced in this agreement, (the Becvar/ChromaDex) Products sold by Licensee and protected by a
valid claim included within Patent Rights.

5.2 In consideration of rights granted by Board to Licensee under this Agreement, Licensee further
agrees to pay Board the following after the execution of a sublicense hereunder:

	 	a.	 	Within 30 days after the execution of the sublicense, a sublicense fee of 5% of any
up-front cash payment made to Licensee in consideration of the sublicense, excluding funds
paid to Licensee for research and development purposes.
	 
	 	b.	 	Within 60 days after the execution of the sublicense, a sublicense fee constituting a
cash payment equal to 10% of any non-cash consideration received by Licensee from a
sublicensee, such consideration to include, without limitation, equity in other companies.
The value of an equity investment will be calculated as the average market value of the
class of stock involved for 5 consecutive days preceding the execution of the sublicense
agreement. In cases where the sublicense agreement calls for payment to Licensee of a
premium over the market value, Board will also share 10% of the premium paid to Licensee.

5.3 During the Term of this Agreement and for 1 year thereafter, Licensee agrees to keep complete
and accurate records of its and its sublicensees’ Sales and Net Sales of Licensed Products under
the license granted in this Agreement in sufficient detail to enable the royalties payable
hereunder to be determined. Licensee agrees to permit Board or its representatives, at Board’s
expense, to periodically but no more than once per annum examine Its books, ledgers, and records
during regular business hours for the purpose of and to the extent necessary to verify any report
required under this Agreement. Any such audit shall be coordinated with auditing requirements under
the Becvar/ChromaDex. agreement cross referenced in this agreement, to prevent duplicate audits in
any calendar year. If the amounts due to Board are determined to have been underpaid by more than
5%, Licensee will pay the cost of the examination and accrued interest at the highest allowable
rate but not more prime rate plus three percent (3%) interest compounded daily on the amount
underpaid.

 

6

 

5.4 Within 60 days following the close of each Calendar Quarter, beginning immediately after the
Effective Date, Licensee must deliver to Board a true and accurate written report, even if no
payments are due Board, giving the particulars of the business conducted by Licenses and its
sublicensee(s), if any exist, during the preceding 3 calendar months under this Agreement as are
pertinent to calculating payments hereunder. This report will Include
at least:

	 	a.	 	the country of sale

	 	b.	 	the date sold;

	 	c.	 	the applicable deductions and calculation of royalties thereon; and

	 	d.	 	the total royalties computed and due Board.

Simultaneously with the delivery of each report, Licensee must pay to Board the amount, if any, due
for the period of each report.

5.5 On or before each anniversary of the Effective Date, irrespective of having a first Sale or
offer for Sale, Licensee must deliver to Board a written progress report as to Licensee’s (and any
sublicensee’s) efforts and accomplishments during the preceding year in diligently commercializing
Licensed Subject Matter in the Licensed Territory and Licensee’s (and, if applicable,
sublicensee’s) commercialization plans for the upcoming year.

5.6 All amounts payable here by Licensee for Licensed Products sold in the United States must be
paid in United States funds without deductions for taxes, assessments, fees, or charges of any
kind. Checks must be payable to the University of Texas at El Paso.

5.7 Currency Conversions/Tax Withholding: Payments shall be made in United States dollars to the
extent that conversions to United States dollars are permitted. The rate of exchange to be used in
any such conversion from the currency in the country where such Net Sales are made shall be the
commercial rate of exchange prevailing in the United States on the last day of the Calendar Quarter
calculated using the exchange rate (local currency, per US$1) published in The Wall Street Journal,
Western Edition, under the heading “Currency Trading.” If due to restrictions or prohibitions
Imposed by national or international authority, royalties in any country cannot be remitted to
Licensor within six (6) months after the end of the Calendar Quarter during which they are earned,
then Licensee shall be obligated to deposit the royalties in a bank account in such country in the
name of Licensor or Licensor’s designee. If Licensee concludes that tax withholdings under the laws
of any country are required with respect to payments to Licensor, Licensee may deduct and pay to
the appropriate governmental authorities the amount required to be withheld from the amount due
Licensor and provide to Licensor reasonable evidence of such_payment.

 

7

 

5.8
Licensee must reimburse Board for all its out-of-pocket expenses thus far incurred in filing,
prosecuting, enforcing and maintaining exclusively licensed Patent Rights and must pay all future
expenses so long as and in the countries its license remains exclusive.

6. TERM AND TERMINATION

6.1 The term of this Agreement is from the Effective Date to the full end of the term or terms for
which Patent Rights have not expired or, if only Technology Rights are licensed and no Patent
Rights are applicable, for a term of 15 years.

6.2 Any time after 2 years from the Effective Date, Board and University have the right to
terminate the exclusivity of this license in any national political jurisdiction in the Licensed
Territory if Licensee, within 90 days after receiving written notice from University of intended
termination of exclusivity, fails to provide written evidence satisfactory to University that
Licensee or its sublicensee’s has commercialized or is actively attempting to commercialize a
licensed invention in such jurisdiction(s), provided, however, that, notwithstanding the foregoing,
if Licensee has reported Net Sales of the following amounts for the periods indicated Licensee will
be deemed to have satisfied the commercialization requirements of this paragraph for all
territories:

	 	(i)	 	Second year: two hundred thousand dollars ($200,000)

	 	(ii)	 	Third and Fourth years; five hundred thousand dollars ($500,000) each year

	 	(iii)	 	Fifth and Sixth years: one million dollars ($1,000,000) each year

	 	(iv)	 	Thereafter $2,000,000 each year

6.3 Any time after 3 years from the Effective Date, Board and University have the right to
terminate this license in any national political jurisdiction in the Licensed Territory if
Licensee, within 90 days after receiving written notice from University of intended termination,
fails to provide written evidence satisfactory to University that Licensee or its sublicensees has
commercialized or is actively attempting to commercialize a licensed invention in such
jurisdiction(s), provided, however, that, notwithstanding the foregoing, if Licensee has reported
Net Sales of the following amounts for the periods indicated Licensee will be deemed to have
satisfied the commercialization requirements of this paragraph for all territories:

	 	(i)	 	Second year: two hundred thousand dollars ($200,000)

	 	(ii)	 	Third and Fourth years: five hundred thousand dollars ($500,000) each year

	 	(iii)	 	Fifth and Sixth years: one million dollars ($1,000,000) each year

	 	(iv)	 	Thereafter $2,000,000 each year

 

8

 

6.4 The
following definitions apply to Article 6: (i) “Commercialize” means having Sales of
Licensed Products in such jurisdiction; and (ii) “Active attempts to commercialize” means having
Sales of Licensed Products or an effective, ongoing and active research, development,
manufacturing, marketing or sales program as appropriate, directed toward obtaining regulatory
approval, production or Sales of Licensed Products in any jurisdiction, and plans acceptable to
University, in its sole discretion, to commercialize licensed inventions in the jurisdiction(s)
that University intends to terminate.

6.5 This Agreement will earlier terminate automatically if Licensee becomes bankrupt or insolvent
and/or if the business of Licensee is placed in the hands of a receiver, assignee, or trustee,
whether by voluntary act of Licensee or otherwise; or

	 	a.	 	upon 90 days written notice from Board if Licensee breaches or defaults on its
obligation to make payments (if any are due) or reports, in accordance with the terms of
Article 5, unless, before the end of the 90 day period,
Licensee has cured the default or
breach and so notifies Board, stating the manner of the cure and provided that if there is
a dispute submitted to arbitration, the notice and cure period will not commence until the
later of the completion of the arbitration; or

	 	b.	 	upon 90 days written notice if Licensee breaches or defaults on any other obligation
under this Agreement, unless, before the end of the 90 day period, Licensee has cured the
default or breach and so notifies Board, stating the manner of the cure and provided that
if there is a dispute submitted to arbitration, the notice and cure period will not
commence until the later of the completion of the arbitration; or

	 	c.	 	at any time by mutual written agreement between Licensee, University and Board, upon
180 days written notice to all parties and subject to any terms herein which survive
termination; or

	 	d.	 	under the provisions of Paragraphs 6.2 and 6.3 if invoked.

6.6 If this Agreement is terminated for any cause:

	 	a.	 	nothing herein will be construed to release either party of any obligation matured
prior to the effective date of the termination;

	 	b.	 	after the effective date of the termination, Licensee may sell all Licensed Products
and parts therefore it has on hand at the date of termination, if it pays earned royalties
thereon according to the terms of Article 5; and

	 	c.	 	Licensee will be bound by the provisions of Articles 10 (Indemnification), 11 (Use of
Board and Component’s Name), and 12 (Confidential Information) of this Agreement.

 

9

 

7. INFRINGEMENT BY THIRD PARTIES

7.1. If either PARTY becomes aware of potential infringement of any PATENT RIGHTS, then that
PARTY will notify the other PARTY as soon as possible and the PARTIES agree to discuss and
determine how best to end such infringement. Licensee must pay Board a royalty on any monetary
recovery if the monetary recovery is for damages less any legal expense or a reasonable royalty in
lieu thereof. If Licensee does not file suit against a substantial infringer of a patent within 6
months of knowledge thereof, then Board may enforce any patent licensed hereunder on behalf of
Itself and Licensee, Board retaining all recoveries from such
enforcement.

7.2 In any infringement suit or dispute, the parties agree to cooperate fully with each
other. At the request and expense of the party bringing suit, the other party will permit access
to all relevant personnel, records, papers, information, samples, specimens, etc., during regular
business hours.

8. ASSIGNMENT

Except in connection with the sale of substantially all of Licensee’s assets to a third party, this
Agreement may not be assigned by Licensee without the prior written consent of Board, which will
not be unreasonably withheld; provided, however, Licensee may, without such consent, assign the
Agreement and its rights and obligations hereunder in connection with the transfer or sale of all
or substantially all of its assets related to the division or the subject business, or in the event
of its merger or consolidation or change in control or similar transaction.

9. PATENT MARKING

Licensee must permanently and legibly mark all products and documentation manufactured or sold
by it under this Agreement with a patent notice as may be permitted or required under
Title 35, United States Code.

10. INDEMNIFICATION AND INSURANCE

10.1 Licensee agrees to hold harmless and indemnify Board, System, University, its Regents,
officers, employees and agents from and against any claims, demands, or causes of action
whatsoever, including without limitation those arising on account of any injury or death of
persons or damage to property caused by, or arising out of, or resulting from, the exercise or
practice of the license granted hereunder by Licensee, its Affiliates or their officers,
employees, agents or representatives.

10.2 In no event shall Board be liable for any indirect, special, consequential or punitive
damages (including, without limitation, damages for loss of profits or expected savings or
other economic losses, or for injury to persons or property) arising out of or in
connection with this Agreement or its subject matter, regardless of whether Board knows or
should know of the possibility of such damages.

 

10

 

10.3 Insurance

	 	a.	 	Beginning at the time when any Licensed Subject Matter is being distributed or sold
(including for the purpose of obtaining regulatory approvals) by Licensee or by a sublicensee,
Licensee shall, at its sole cost and expense, procure and maintain commercial general liability
insurance in amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate, and
Licensee shall use reasonable efforts to have the Board, System, University, its Regents, officers,
employees and agents named as additional insured’s. Such commercial general liability insurance
shall provide (i) product liability coverage; (ii) broad form contractual liability coverage for
Licensee’s indemnification under this Agreement; and (iii) coverage for litigation costs. The
minimum amounts of insurance coverage required shall not be construed to create a limit of
Licensee’s liability with respect to its indemnification under this Agreement.

	 	b.	 	Licensee shall provide Board with written evidence of such insurance upon Board’s request.
Licensee shall provide Board with written notice of at least fifteen (15) days prior to the
cancellation, non-renewal or material change in such insurance.

	 	c.	 	Licensee shall maintain such commercial general liability insurance beyond the expiration or
termination of this Agreement during (i) the period that any Licensed Subject Matter
developed pursuant to this Agreement is being commercial distributed or sold by Licensee or
by a sublicensee or agent of Licensee; and (ii) the five (5) year period immediately after
such period.

11. USE OF BOARD AND COMPONENT’S NAME

Licensee may not use the name of University, System or Board without express written consent.

12. CONFIDENTIAL INFORMATION AND PUBLICATION

12.1 Board and Licensee each agree that all information contained in documents marked
“confidential” and forwarded to one by the other (i) be received in strict confidence, (ii) be
used only for the purposes of this Agreement, and (iii) not be disclosed by the recipient party,
its agents or employees without the prior written consent of the other party, except to the
extent that the recipient party can establish competent written proof that such information;

	 	a.	 	was in the public domain at the time of disclosure;

	 	b.	 	later became part of the public domain through no act or omission of the recipient
party, it’s employees, agents, successors or assigns;

 

11

 

	 	c.	 	was lawfully disclosed to the recipient party by a third party having the right to
disclose it;

	 	d.	 	was already known by the recipient party at the time of disclosure;

	 	e.	 	was independently developed by the recipient; or

	 	f.	 	is required by law or regulation to be disclosed.

12.2 Each party’s obligation of confidence hereunder shall be fulfilled by using at least the same
degree of care with the other party’s confidential information as it uses to protect its own
confidential information. This obligation shall exist while this Agreement is in force and for a
period of 3 years thereafter.

12.3 University will submit its manuscript for any proposed publication of research related to
Licensed Subject Matter to Licensee at least 30 days before publication, and Licensee shall have
the right to review and comment upon the publication in order to protect Licensee’s confidential
information. Upon Licensee’s request. publication will be delayed up to 60 additional days to
enable Licensee to secure adequate intellectual property protection of Licensee’s property that
would be affected by the publication. For the purposes of this clause “publication” shall mean any
public disclosure as defined under patent law.

13. PATENTS AND INVENTIONS

13.1 Both parties agree to fully cooperate with each other concerning patent matters, including
selection and use of patent counsel. If after consultation with Licensee, both parties agree that a
patent application should be filed for Licensed Subject Matter, Board will prepare and file the
appropriate patent applications, and Licensee will pay the cost of searching, preparing, filing,
prosecuting and maintaining same. If Licensee notifies Board that it does not intend to pay the
cost of an application, or if Licensee does not respond or make an effort to agree with Board on
the disposition of rights in the subject invention, then Board may file an application at its own
expense and Licensee will have no rights to the invention in the territory in question; provided,
however, that If Licensee has filed applications in the United States, at least three major
territories within the European Union and Japan, Licensee will retain exclusive rights worldwide.
Board will provide Licensee a copy of any patent application for which Licensee has paid the cost
of filing, as well as copies of any documents received or filed with the respective patent office
during the prosecution thereof.

 

12

 

14. ALTERNATE DISPUTE RESOLUTION

14.1 Any dispute or controversy arising out of or relating to this Agreement, its construction or
its actual or alleged breach will be decided by mediation, If the mediation does not result in a
resolution of such dispute or controversy, it will be finally decided by an appropriate method of
alternate dispute resolution, including without limitation, arbitration, conducted in the city of
El Paso, Texas in accordance with the Commercial Dispute Resolution Procedures of the American
Arbitration Association. The arbitration panel will include members knowledgeable in the
evaluation of biotechnology and chemical technology. Judgment upon the award rendered may be
entered in the highest court or forum having jurisdiction, state or federal. The provisions of this
Article 14 will not apply to decisions on the validity of patent claims or to any dispute or
controversy as to which any treaty or law prohibits such arbitration. The decision of the
arbitration must be sanctioned by a court of law having jurisdiction to be binding upon and
enforceable by the parties.

15. GENERAL

15.1 This Agreement constitutes the entire and only agreement between the parties for Licensed
Subject Matter and all other prior negotiations, representations, agreements, and understandings
are superseded hereby. No agreements altering or supplementing the terms hereof may be made except
by a written document signed by both parties.

15.2 Any notice required by this Agreement must be given by prepaid, first class, certified
mail, return receipt requested and addressed to:

The University of Texas at El Paso

Technology Transfer Office

Burges Hall, Room 404

500 W. University

El Paso, Texas 79968

Attn: Technology Transfer Manager

Ph: 915/747-7901

Fax: 915/747-5931

or in the case of Licensee to:

ChromaDex

2952 Daimler St.

Santa Ana, California 92705

Attn: Mr. Frank Jaksch

Fax: 949/419-0894

Phone: 949/419-0288

or other addresses as may be given from time to time under the terms of this notice provision.

 

13

 

15.3 Licensee must comply with all applicable federal, state and local laws and
regulations in connection with its activities pursuant to this Agreement.

15.4 This Agreement will be construed and enforced in accordance with the laws of the United
States of America and of the State of Texas.

15.5 Failure of Board to enforce a right under this Agreement will not act as a waiver of that
right or the ability to later assert that right relative to the particular situation involved.

15.6 Headings are included herein for convenience only and shall not be used to construe
this Agreement.

15.7 If any part of this Agreement is for any reason found to be unenforceable, all other
parts nevertheless remain enforceable.

IN
WITNESS WHEREOF, parties hereto have caused their duly authorized representatives to execute
this Agreement.

	 	 	 	 	 	 	 	 	 	 	 
	BOARD OF REGENTS OF THE	 	 	 	CHROMADEX	 	 
	UNIVERSITY OF TEXAS SYSTEM	 	 	 	 	 	 	 	 
	 

	 	 	 	 
	 	 	 	 	 	 
	By

	 	 	 	 	 	By
	 	/s/ Frank Jaksch	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Diana S. Natalicio, President
	 	 	 	 	 	Frank Jaksch, President	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	 	 	 	 	Date:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Approved as to Content:	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	Paul C. Maxwell, Vice President for Research  	 	 	 	 	 	 	 	 
	 

	 	 and Sponsored Projects	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 

 

14Filed by Bowne Pure Compliance

Exhibit 10.13

STOCK REDEMPTION AGREEMENT

This
STOCK REDEMPTION AGREEMENT (this “Agreement”) is
made and entered into as of this 18th day of June 2008, by and between ChromaDex, Inc., a California corporation (the
“Corporation”), and Bayer Innovation GmbH (formerly named Bayer Innovation
Beteiligungsgesellschaft mbH), a German corporation (“Shareholder”).

R E C I T A L S

A. Shareholder is the owner of 1,222,795 shares of the Common Stock of the Corporation (the
“Shares”).

B. The Corporation desires to redeem from Shareholder, and Shareholder desires to sell to the
Corporation, all of the Shares, on the terms and subject to the conditions of this Agreement.

A G R E E M E N T

In consideration of the foregoing recitals and the mutual covenants contained herein, the
parties, intending to be legally bound, agree as follows:

1. Redemption of Securities. Shareholder hereby sells, transfers and assigns to the
Corporation, and the Corporation hereby purchases and redeems from Shareholder, all of
Shareholder’s right, title and interest in and to the Shares.

2. Consideration. As consideration for the sale to the Corporation of the Shares hereunder,
on or before December 20, 2008 (the “Payment Date”), the Corporation shall pay to
Shareholder US$1,002,691.90 (the “Purchase Price”), or US$0.82 per share of Common Stock,
by the Corporation’s delivery to Shareholder of a wire transfer of immediately available funds in
such amount. Concurrently with the execution of this Agreement, the Corporation shall issue a
promissory note in favor of Shareholder reflecting the Corporation’s payment obligations under this
Section 2, in the form attached to this Agreement as Annex A (the “Promissory
Note”). As set forth in the Promissory Note, and not in addition thereto, if the principal
amount of the Promissory Note, or any part thereof, is not paid in full when due, the Corporation
shall pay interest on the overdue principal amount at the rate of one and one half percent (1 1/2%)
per month beginning January 1, 2009 until all amounts outstanding under this Promissory Note have
been paid in full, or at the maximum rate permitted by applicable law, whichever is less. Interest
shall be computed on the basis of the actual number of days outstanding on the basis of a year
consisting of 360 days. Borrower may prepay the Promissory Note without premium or penalty. All
payments received on account of the Promissory Note shall be first applied to accrued and unpaid
interest, if any, and the remainder shall be applied to the reduction of principal.

 

 

 

3. Representations and Warranties. Shareholder hereby represents and warrants to the
Corporation as follows:

3.1
Authorization. All action has been taken on the part of Shareholder necessary for the
authorization, execution and delivery of this Agreement. Shareholder has taken all action required
to make all the obligations of Shareholder reflected herein the valid and enforceable obligations
they purport to be.

3.2
Compliance with Other Instruments. The authorization, execution, delivery and
consummation of this Agreement will not constitute or result in a default or violation of any law
or regulation applicable to Shareholder or any term or provision of Shareholder’s charter
documents, or any material agreement or instrument by which it is bound or to which its properties
or assets are subject.

3.3 Ownership; Right to Transfer. Shareholder owns beneficially the Shares free and clear of
all liens, encumbrances, security interests, claims, options or limitations affecting its ability
to transfer the Shares to the Corporation. Shareholder has the unrestricted right to enter into
this Agreement and to consummate the transactions described in this Agreement without obtaining the
consent or approval of any third party.

3.4 Exclusion of Liability. Shareholder does not provide any other representations or
warranties and any and all claims for breach of representations or warranties other than the ones
specified above shall be waived by the Corporation and excluded to the extent legally possible.

4. Representations and Warranties. The Corporation hereby represents and warrants to
Shareholder as follows:

4.1
Authorization. All action has been taken on the part of the Corporation necessary for the
authorization, execution and delivery of this Agreement. The Corporation has taken all action
required to make all the obligations of the Corporation reflected herein the valid and enforceable
obligations they purport to be.

4.2
Compliance with Other Instruments. The authorization, execution, delivery and
consummation of this Agreement will not constitute or result in a default or violation of any law
or regulation applicable to the Corporation or any term or provision of the Corporation’s charter
documents, or any material agreement or instrument by which it is bound or to which its properties
or assets are subject.

4.3
Agreement and Plan of Merger. The Merger (as defined in that certain Agreement and Plan
of Merger, dated May 21, 2008, by and among Cody Resources, Inc., a Nevada corporation, CDI
Acquisition, Inc., a California corporation, and the Corporation) has not yet been made effective
and will not be made effective before the Effective Time (as defined in Section 5).

4.4 Exclusion of Liability. The Corporation does not provide any other representations or
warranties and any and all claims for breach of representations or warranties other than the ones
specified above shall be waived by Shareholder and excluded to the extent legally possible.

 

2

 

5. Closing.

5.1 Closing; Effective Time. The consummation of the transactions contemplated herein (the
“Closing”) shall take place remotely by exchange of documents and signature pages via
facsimile or electronic mail, to be coordinated from the offices of Manatt, Phelps & Philips, LLP,
695 Town Center Drive, Fourteenth Floor, Costa Mesa California 92626, and shall be effective upon
delivery and release of the documents and instruments set forth in Sections 5.2 and 5.3 (the
“Effective Time”).

5.2 Shareholder’s Obligations at Closing. At the Closing, Shareholder shall deliver, or cause
to be delivered, to the Corporation, the following documents and instruments, in form and substance
reasonably satisfactory to the Corporation and its counsel:

(a) A counterpart signature page to this Agreement, duly executed by Shareholder;

(b) A stock assignment separate from certificate, duly executed by Shareholder, assigning all
of its right, title and interest in and to the Shares, as evidenced by Stock Certificate No. 24 of
the Corporation; and

(c) Such other documents and instruments as the Corporation or its counsel may reasonably
request to better evidence or effectuate the transactions contemplated hereby.

5.3 Obligations of the Corporation at Closing. At the Closing, the Corporation shall deliver
to Shareholder the following documents and instruments, in form and substance reasonably
satisfactory to Shareholder and his counsel:

(a) A counterpart signature page to this Agreement, duly executed by the Corporation;

(b) The Promissory Note, duly executed by the Corporation; and

(c) Such other documents and instruments as Shareholder or its counsel may reasonably request
to better evidence or effectuate the transactions contemplated hereby.

5.4 Obligations of the Parties After Closing. As soon as practicable after the Closing, but
in no event more than three business days thereafter, (a) each of the Corporation and Shareholder
shall send by courier to the other, an originally executed counterpart of the documents and
instruments set forth in Sections 5.2 and 5.3, and (b) Shareholder shall send by
courier to the Corporation for cancellation, the original Stock Certificate No. 24 of the
Corporation.

 

3

 

6. General Provisions.

6.1 Governing Law. This Agreement and all acts and transactions pursuant hereto and the
rights and obligations of the parties shall be governed, construed and interpreted in accordance
with the laws of the State of California.

6.2 Entire Agreement. This Agreement, together with the exhibits attached hereto, sets forth
the entire understanding of the parties relating to the subject matter herein and merges all prior
discussions between them.

6.3 Enforcement of Rights. No modification of or amendment to this Agreement, nor any waiver
of any rights under this Agreement, shall be effective unless in writing signed by the parties to
this Agreement. The failure by either party to enforce any rights under this Agreement shall not
be construed as a waiver of any rights of such party.

6.4 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original and all of which together shall constitute one instrument.

6.5 Severability. Should one or more provisions of this Agreement be or become invalid,
illegal or unenforceable in whole or in part or should it turn out that this Agreement is
incomplete, the validity or enforceability of the remaining provisions hereof shall not be
affected. In such event the parties hereto shall be obliged to replace the invalid, illegal or
unenforceable provision by, or to complete this Agreement with, a valid and enforceable provision
which most closely resembles the economic and legal purpose of the invalid or unenforceable
provision.

IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the date first
set forth above.

	 	 	 	 	 	 	 	 	 	 	 
	THE “CORPORATION”:	 	 	 	“SHAREHOLDER”	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	CHROMADEX, INC.,	 	 	 	BAYER INNOVATION GMBH,	 	 
	a California corporation	 	 	 	a German corporation	 	 
	 

	 	 	 	 
	 	 	 	 	 	 
	By:

	 	/s/ Frank Jaksch, Jr.
	 	 	 	By:
	 	/s/ Dr. Detlef Wollweber	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Frank Jaksch, Jr.
	 	 	 	 
	 	Name: Dr. Detlef Wollweber	 	 
	 

	 	Chief Executive Officer
	 	 	 	
	 	Title: Managing
Director/Geschäftsführer	 	 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}]]